US presidential election, health policy will remain a key issue for pharma. Both Donald Trump and Kamala Harris have ...

Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity.

The UK’s MHRA has approved Takeda’s Fruzaqla (fruquintinib) for metastatic colorectal cancer (CRC) in adults who have not ...

Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of ...

Leslie Orne, president and CEO of Trinity Life Sciences, emphasizes the importance of corporate efficiency in the highly ...

BioXcel Therapeutics has announced a clinical reprioritization, focusing on late-stage development of its agitation treatment ...

Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...

Eurofins Genomics US has opened a new oligonucleotide manufacturing facility, expanding its capacity to meet growing global demand for GMP-grade and research use oligonucleotides. The facility will ...

Aligos Therapeutics (Nasdaq: ALGS) has announced positive top-line results from the Phase IIa HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction ...

Achilles Therapeutics has announced it will discontinue its tumor-infiltrating lymphocyte (TIL)-based clonal neoantigen T ...

Sanofi has reported positive results from its Phase III HERCULES trial of tolebrutinib for non-relapsing secondary ...

The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...